NVO
Novo Nordisk A/S
37.50$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 60.1% | 60.1% | 61.3% | 58.7% | 53.3% | 49.7% | 45.4% | 44.0% | 44.8% | 44.4% | 34.5% | 31.8% | |
| 18.7% | 18.4% | 19.2% | 18.4% | 14.1% | 12.3% | 8.8% | 5.5% | 5.2% | 4.6% | 3.4% | 4.9% | |
| 20.6% | 22.3% | 21.2% | 18.4% | 14.1% | 12.3% | 8.8% | 9.0% | 9.8% | 9.6% | 5.6% | 5.0% | |
| 20.5% | 19.3% | 24.8% | 23.0% | 24.3% | 20.5% | 19.3% | 24.1% | 23.8% | 23.9% | 18.8% | 13.9% | |
| 14.7% | 13.9% | 14.7% | 15.0% | 14.7% | 14.0% | 12.8% | 10.1% | 10.1% | 10.1% | 8.8% | 9.1% | |
| 4.9% | 27.8% | 30.9% | 34.4% | 37.8% | 267.9% | 211.0% | 28.5% | 27.6% | 28.9% | 34.9% | 38.4% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.2% | 2.1% | 1.4% | 4.3% | 3.7% | |
| 1.8% | 2.4% | 2.8% | 3.2% | 4.6% | 4.6% | 14.3% | 20.0% | 19.2% | 17.8% | 19.5% | 20.3% | |
| 47.7% | 48.8% | 53.6% | 51.3% | 53.2% | 54.2% | 56.3% | 63.6% | 65.4% | 66.1% | 69.2% | 64.3% | |
| 43.7% | 44.5% | 48.6% | 46.0% | 48.9% | 47.0% | 48.5% | 51.2% | 50.1% | 53.9% | 46.7% | 39.7% | |
| 0.9% | 1.2% | 0.2% | 1.7% | 0.5% | 1.2% | 5.1% | 7.0% | 0.6% | 2.1% | 2.8% | 2.2% | |
| 6.4% | 5.4% | 6.2% | 5.5% | 6.1% | 5.1% | 3.9% | 4.6% | 6.5% | 8.1% | 6.2% | 3.6% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 5.0% | 8.6% | 5.1% | 18.1% | 21.9% | |
| 52.3% | 51.2% | 46.4% | 48.7% | 46.8% | 45.8% | 43.7% | 36.4% | 34.6% | 33.9% | 30.8% | 35.7% | |
| 53.6% | 51.0% | 47.3% | 47.9% | 48.2% | 46.0% | 44.0% | 37.0% | 33.4% | 33.3% | 31.0% | 36.0% | |
| 6.8% | 5.6% | 5.2% | 4.8% | 4.4% | 25.2% | 19.6% | 2.4% | 1.9% | 1.4% | 1.0% | 0.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.